MAP2K7 and non-small cell lung carcinoma: Recently, a combination of encorafenib (anti-BRAF) 450 mg once daily plus binimetinib (anti-MEK) 45 mg twice daily in 28-day cycles also showed clinically meaningful antitumor activity in two phase II trials, either in untreated (ENCOBRAF trial: ORR 66.7%, mPFS 11.1 months; PHAROS trial: ORR 75%, PFS 30.2 months) or pre-treated (PHAROS trial: ORR 46%, mPFS 9.3 months) patients with advanced BRAF-V600E NSCLC, and was approved in this setting [16].